Your browser doesn't support javascript.
loading
Synthesis, In Vitro, In Vivo and In Silico Antidiabetic Bioassays of 4-Nitro(thio)phenoxyisobutyric Acids Acting as Unexpected PPARγ Modulators: An In Combo Study.
Colin-Lozano, Blanca; Torres-Gomez, Héctor; Hidalgo-Figueroa, Sergio; Chávez-Silva, Fabiola; Estrada-Soto, Samuel; Almanza-Pérez, Julio Cesar; Navarrete-Vazquez, Gabriel.
Afiliação
  • Colin-Lozano B; Facultad de Farmacia, Universidad Autónoma del Estado de Morelos, Cuernavaca, Morelos 62209, Mexico.
  • Torres-Gomez H; Facultad de Ciencias Químicas, Benemérita Universidad Autónoma de Puebla, Puebla 72000, Mexico.
  • Hidalgo-Figueroa S; Facultad de Farmacia, Universidad Autónoma del Estado de Morelos, Cuernavaca, Morelos 62209, Mexico.
  • Chávez-Silva F; Leibniz Institute for Natural Products and Infection Biology, Hans Knöll Institute, 07745 Jena, Germany.
  • Estrada-Soto S; Facultad de Farmacia, Universidad Autónoma del Estado de Morelos, Cuernavaca, Morelos 62209, Mexico.
  • Almanza-Pérez JC; CONACyT, Instituto Potosino de Investigación Científica y Tecnológica, San Luis Potosi 78216, Mexico.
  • Navarrete-Vazquez G; Facultad de Farmacia, Universidad Autónoma del Estado de Morelos, Cuernavaca, Morelos 62209, Mexico.
Pharmaceuticals (Basel) ; 15(1)2022 Jan 15.
Article em En | MEDLINE | ID: mdl-35056159
Four isobutyric acids (two nitro and two acetamido derivatives) were prepared in two steps and characterized using spectral analysis. The mRNA concentrations of PPARγ and GLUT-4 (two proteins documented as key diabetes targets) were increased by 3T3-L1 adipocytes treated with compounds 1-4, but an absence of in vitro expression of PPARα was observed. Docking and molecular dynamics studies revealed the plausible interaction between the synthesized compounds and PPARγ. In vivo studies established that compounds 1-4 have antihyperglycemic modes of action associated with insulin sensitization. Nitrocompound 2 was the most promising of the series, being orally active, and one of multiple modes of action could be selective PPARγ modulation due to its extra anchoring with Gln-286. In conclusion, we demonstrated that nitrocompound 2 showed strong in vitro and in vivo effects and can be considered as an experimental antidiabetic candidate.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Pharmaceuticals (Basel) Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Pharmaceuticals (Basel) Ano de publicação: 2022 Tipo de documento: Article